profit from every $100 of sales.
$0$100
Monopar Therapeutics
$71.78-2.67% today
-13.6% in 1 year
1-year low $50.121-year high $123.84
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Monopar Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$13.7 million of profit last year.
SalesProfit
Monopar Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Monopar Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Monopar Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -11 | -9 | -16 | -17 | |
| -11 | -9 | -16 | -17 | |
| -11 | -8 | -16 | -14 | |
| -4.15 | -3.04 | -4.11 | -1.85 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 13 | 7 | 60 | 141 |
| Cash | 8 | 7 | 46 | 62 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 3 | 2 | 5 | 3 |
| 10 | 6 | 55 | 138 | |
| 3 | 3 | 4 | 7 | |
| -82.4% | -124.9% | -23.2% | -9.6% | |
| -104.2% | -150.4% | -28.3% | -10.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7 | -8 | -6 | -12 | |
| – | – | – | – | |
| -7 | -8 | -6 | -12 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 35 | |
| 2 | 2 | 1 | 5 |
Valuation
- –
- –
- –
- 2.9×
- –
- –
- 2,902.6×
- -2.5%
- -2.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -9.8%
- -61.5%
- -0.0%
- -0.0%
- -0.0%
- –
Growth
- –
- –
- −90.5%
- –
- +42.8%
Financial health
- 2,923.7×
- 0.00
- 0.1%
- –
- 51.35
- 56.04
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 27%of 953
Bottom 21%of 877
Bottom 28%of 988
What analysts expect
- Average price target
- $119.00
- Range
- $115.00 – $123.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.46 | -0.87 | +47.1% |
| Mar 27, 2026 | -0.61 | -0.51 | −19.1% |
| Nov 13, 2025 | -0.48 | -0.46 | −4.3% |
| Aug 12, 2025 | -0.35 | -0.47 | +25.5% |
| May 13, 2025 | -0.38 | -0.65 | +41.5% |
| Mar 31, 2025 | -2.23 | -0.36 | −519.4% |
| Nov 8, 2024 | -0.37 | -0.46 | +19.6% |
| Aug 9, 2024 | -0.50 | -0.45 | −11.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
14No pass
Benjamin Graham
27No pass
Philip Fisher
30No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
22No pass
Questions about Monopar Therapeutics
Is Monopar Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Monopar Therapeutics AI analysis
What does Monopar Therapeutics do?
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. It is in Biotechnology.
Does Monopar Therapeutics pay a dividend?
No. Monopar Therapeutics does not pay a dividend at the moment; in 2025 it returned $35.0 million to shareholders by buying back its own shares.
Is Monopar Therapeutics stock halal?
Yes. Monopar Therapeutics passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Monopar Therapeutics stock done over the past year?
Down 13.6% over the past twelve months, to $71.78. It traded between $50.12 and $123.84 and is 42.0% below its high.
Who are Monopar Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Monopar Therapeutics's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.